1. Home
  2. RDI vs CCEL Comparison

RDI vs CCEL Comparison

Compare RDI & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.06

Market Cap

25.7M

ML Signal

HOLD

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.49

Market Cap

27.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
CCEL
Founded
1937
1989
Country
United States
United States
Employees
2005
N/A
Industry
Movies/Entertainment
Managed Health Care
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
27.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RDI
CCEL
Price
$1.06
$3.49
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
18.2K
9.0K
Earning Date
05-14-2026
04-14-2026
Dividend Yield
N/A
4.26%
EPS Growth
N/A
N/A
EPS
N/A
0.01
Revenue
N/A
$25,384,279.00
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
$345.32
Revenue Growth
N/A
9.76
52 Week Low
$0.94
$2.72
52 Week High
$1.65
$5.52

Technical Indicators

Market Signals
Indicator
RDI
CCEL
Relative Strength Index (RSI) 39.67 48.45
Support Level $0.99 $3.18
Resistance Level $1.16 $3.57
Average True Range (ATR) 0.05 0.29
MACD -0.01 -0.03
Stochastic Oscillator 15.80 11.59

Price Performance

Historical Comparison
RDI
CCEL

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

Share on Social Networks: